Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors.

Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE.

Cancer Res. 2004 Feb 15;64(4):1266-77.

2.
5.

Study of EWS/FLI-1 rearrangement in 18 cases of CK20+/CM2B4+ Merkel cell carcinoma using FISH and correlation to the differential diagnosis of Ewing sarcoma/peripheral neuroectodermal tumor.

Fernandez-Flores A, Suarez-Pe├▒aranda JM, Alonso S.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):379-85. doi: 10.1097/PAI.0b013e318273a9e0.

PMID:
23165331
6.

Alternative EWS-FLI1 fusion gene and MIC2 expression in peripheral and central primitive neuroectodermal tumors.

Ishii N, Hiraga H, Sawamura Y, Shinohe Y, Nagashima K.

Neuropathology. 2001 Mar;21(1):40-4.

PMID:
11304041
7.

EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.

González I, Vicent S, de Alava E, Lecanda F.

J Mol Med (Berl). 2007 Sep;85(9):1015-29. Epub 2007 Apr 24.

PMID:
17453169
8.

The Ews/Fli-1 fusion gene changes the status of p53 in neuroblastoma tumor cell lines.

Rorie CJ, Weissman BE.

Cancer Res. 2004 Oct 15;64(20):7288-95.

9.

Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases.

Jimenez RE, Folpe AL, Lapham RL, Ro JY, O'Shea PA, Weiss SW, Amin MB.

Am J Surg Pathol. 2002 Mar;26(3):320-7.

PMID:
11859203
10.

Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.

Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V.

Cancer Res. 2006 Oct 15;66(20):9937-47.

11.
12.

Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma.

Eliazer S, Spencer J, Ye D, Olson E, Ilaria RL Jr.

Mol Cell Biol. 2003 Jan;23(2):482-92.

13.

Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.

Takigami I, Ohno T, Kitade Y, Hara A, Nagano A, Kawai G, Saitou M, Matsuhashi A, Yamada K, Shimizu K.

Int J Cancer. 2011 Jan 1;128(1):216-26. doi: 10.1002/ijc.25564.

14.

Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone.

Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, Gronchi A, Navarria P, Sozzi G, Pilotti S.

Am J Surg Pathol. 2003 Aug;27(8):1161-6.

PMID:
12883251
15.

Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.

Watanabe G, Nishimori H, Irifune H, Sasaki Y, Ishida S, Zembutsu H, Tanaka T, Kawaguchi S, Wada T, Hata J, Kusakabe M, Yoshida K, Nakamura Y, Tokino T.

Genes Chromosomes Cancer. 2003 Mar;36(3):224-32.

PMID:
12557222
16.

EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.

Zhou Z, Yu L, Kleinerman ES.

Cancer. 2014 Feb 15;120(4):579-88. doi: 10.1002/cncr.28555. Epub 2014 Jan 10.

18.

EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor.

Ida K, Kobayashi S, Taki T, Hanada R, Bessho F, Yamamori S, Sugimoto T, Ohki M, Hayashi Y.

Int J Cancer. 1995 Nov 15;63(4):500-4.

PMID:
7591257
19.

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.

Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, Wright RD, Lessnick SL, Kung AL, Golub TR.

PLoS Med. 2007 Apr;4(4):e122.

20.

Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.

Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ, Kim SJ.

Nat Genet. 1999 Oct;23(2):222-7. Erratum in: Nat Genet 1999 Dec;23(4):481.

PMID:
10508522

Supplemental Content

Support Center